Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2022-01-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1696 |